Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375842 · ClinicalTrials.gov registry record · Phase 1
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 661
- Enrollment target
NCT01375842 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 661 participants.
The verdict
NCT01375842, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 661 participants
- Enrollment target
Study Summary
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.
Interventions
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2011-06-21 |
| Est. Completion | 2018-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01375842
The ClinicalTrials.gov registry entry for NCT01375842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 661 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab is the first listed.
NCT01375842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01375842 about?
NCT01375842 is a clinical study titled "A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors". This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. The s...
What is the current status of trial NCT01375842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 661 participants. The study started on 2011-06-21. Estimated completion is 2018-09-30.
What interventions are being tested in trial NCT01375842?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT01375842?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.